Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human modular phase I-IIa study of CP-506 in hypoxia-associated HRD/FAD solid tumors
2023-506818-45-00Phase 2Authorised
- Sponsor
- Convert Pharmaceuticals
- Start
- Jun 2024
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of cp-506 in Nonhematologic neoplasms (3 arms), sponsored by Convert Pharmaceuticals. Primary endpoints: Safety and tolerability of CP-506 and Pharmacokinetics of CP-506. Planned start Jun 2024; status: authorised.
02
Drugs
cp-506
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2023-506818-45-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506818-45-00.